Translating Benzodiazepine Utilization Data into Meaningful Population Exposure: Integration of Two Metrics for Improved Reporting
- 115 Downloads
Drug utilization research on benzodiazepines remains important for measuring trends in consumption within and across borders over time for the sake of monitoring prescribing patterns and identifying potential population safety concerns. The defined daily dose (DDD) system by the World Health Organization (WHO) remains the internationally accepted standard for measuring drug consumption; however, beyond consumption, DDD-based results are difficult to interpret when individual agents are compared with one another or are pooled into a total class-based estimate. The diazepam milligram equivalent (DME) system provides approximate conversions between benzodiazepines and Z-drugs (i.e. zopiclone, zolpidem, zaleplon) based on their pharmacologic potency. Despite this, conversion of total dispensed benzodiazepine quantities into DME values retains diazepam milligrams as the total unit of measurement, which is also impractical for population-level interpretation. In this paper, we propose the use of an integrated DME-DDD metric to obviate the limitations encountered when the component metrics are used in isolation. Through a case example, we demonstrate significant change in results between the DDD and DME-DDD method. Unlike the DDD method, the integrated DME-DDD metric offers estimation of population pharmacologic exposure, and enables superior interpretation of drug utilization results, especially for drug class summary reporting.
The authors thank Mr. Kevin Friesen and Dr. James Bolton for their helpful comments and feedback during the various stages of manuscript preparation. They also thank the anonymous peer reviewers for challenging the presented concepts, leading to subsequent strengthening of the manuscript.
Compliance with Ethical Standards
Conflict of interest
Jaden Brandt, Wajd Alkabanni, Silvia Alessi-Severini, and Christine Leong have no conflicts of interest or disclosures to report.
No funding was received to support the work of this manuscript.
- 14.Ashton H. Benzodiazepine Equivalence Table. http://www.benzo.org.uk/bzequiv.htm. Published 2007. Accessed 3 Feb 2017.
- 19.WHO Collaborating Centre for Drug Statistics Methodology and Norweigan Institute of Public Health. Guidelines for ATC Classification and DDD Assignment—2017. Oslo; 2017.Google Scholar
- 20.WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2018. https://www.whocc.no/atc_ddd_index/. Published 2017. Accessed 23 Feb 2018.
- 23.Bandelow B, Zohar J, Hollander E, Kasper S, Moller H-J. World Federation of Societies of Biological Psychiatry (WfSBP) Guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and psttraumatic stress disorders. World J Biol Psychiatry. 2008;9(4):248–312.CrossRefPubMedGoogle Scholar
- 24.Stein MB, Goin MK, Pollack HM, Roy-Byrne P, Sareen J, Campbell-Sills L. Practice guideline for the Treatment of Patients With Panic Disorder. Am Psychiatr Assoc. 2010;2:1–90.Google Scholar
- 30.Strand MC, Mørland J, Slørdal L, et al. Conversion factors for assessment of driving impairment after exposure to multiple benzodiazepines/z-hypnotics or opioids. Forensic Sci Int. 2016;2017(281):29–36.Google Scholar
- 31.Busse J, Guyatt G, Carrasco A, Akl E, Agoritsas T. The 2017 Canadian guideline for opioids for chronic non-cancer pain. Hamilton, ON; 2017Google Scholar